GSK 2239633A

Pricing Availability   Qty
Description: Potent CCR4 antagonist
Chemical Name: N-[[3-[[3-[[(5-Chloro-2-thienyl)sulfonyl]amino]-4-methoxy-1H-indazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methylpropanamide
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for GSK 2239633A

GSK 2239633A is a potent CCR4 antagonist (pIC50 = 7.83 in a 35S-GTPγS competition assay). Inhibits thymus activation-regulated chemokine (TARC) -induced F-actin polymerization in human whole blood.

Technical Data for GSK 2239633A

M. Wt 549.06
Formula C24H25ClN4O5S2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1240516-71-5
PubChem ID 46861584
Smiles COC1=C2C(NS(=O)(C3=CC=C(S3)Cl)=O)=NN(C2=CC=C1)CC4=CC(CNC(C(C)(O)C)=O)=CC=C4

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for GSK 2239633A

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 54.91 100

Preparing Stock Solutions for GSK 2239633A

The following data is based on the product molecular weight 549.06. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.82 mL 9.11 mL 18.21 mL
5 mM 0.36 mL 1.82 mL 3.64 mL
10 mM 0.18 mL 0.91 mL 1.82 mL
50 mM 0.04 mL 0.18 mL 0.36 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for GSK 2239633A

References are publications that support the biological activity of the product.

Procopiou et al (2012) Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation. Bioorg.Med.Chem.Lett. 22 2730 PMID: 22437117

If you know of a relevant reference for GSK 2239633A, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Chemokine CC Receptor Antagonists

Keywords: GSK 2239633A, GSK 2239633A supplier, GSK2239633A, CCR4, antagonists, antagonism, potent, TARC, CCL17, thymus, activation-regulated, chemokines, CCL22, macrophage-derived, MDC, Chemokine, CC, Receptors, 7071, Tocris Bioscience

Citations for GSK 2239633A

Citations are publications that use Tocris products.

Currently there are no citations for GSK 2239633A. Do you know of a great paper that uses GSK 2239633A from Tocris? Please let us know.

Reviews for GSK 2239633A

There are currently no reviews for this product. Be the first to review GSK 2239633A and earn rewards!

Have you used GSK 2239633A?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.